DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

HCA·HCA Healthcare, Inc.

$.
-. (-.%)
High
$394.98
Open
$389.60
Market Cap
87.42B
52W High
$556.52
Low
$388.01
P. Close
$394.07
P/E
12.87
52W Low
$330.00
Fwd P/E
11.89
Mean Target
-
Technical Score (1D)
32
SELL
News Sentiment
43
BEARISH
HCA Healthcare reported weaker-than-expected Q1 2026 adjusted EBITDA, driven by cost pressures and workforce reductions. This miss signals potential challenges to margin resilience, despite the company's continued investment in areas like stroke care and new facilities. Investors are now focused on the impact of these cost-saving measures, including non-clinical layoffs, and the broader implications of regulatory headwinds. The company's expansion plans appear to be in conflict with current investor concerns over expenses. Moving forward, watch for updates on the effectiveness of these workforce adjustments and any further commentary on the company's outlook regarding cost controls and regulatory pressures.
Earnings Summary
HCA Healthcare, Inc. is a prominent provider of healthcare services, operating a substantial network of hospitals and related facilities across the United States, offering a comprehensive range of medical and surgical services. The company's operations span inpatient and outpatient care, including critical services like intensive care and emergency services, alongside specialized offerings such as ambulatory surgery centers and urgent care clinics, positioning it as a significant player in the Healthcare sector's Medical Care Facilities industry. In its most recent reported quarters, HCA Healthcare demonstrated a trend of accelerating earnings per share (EPS) growth, with Q3 2025 EPS at $6.96 and Q4 2025 EPS at $8.01, both significantly exceeding their respective estimates and showing a strong upward trajectory from Q1 2025 ($6.45) and Q2 2025 ($6.84). Revenue also saw consistent growth, reaching $19.16 billion in Q3 2025 and $19.51 billion in Q4 2025, indicating a positive performance trend. Historically, HCA Healthcare has shown a pattern of beating analyst estimates for EPS, with notable beats in Q3 and Q4 of 2025, contributing to a generally positive earnings streak. The company has also managed to grow revenue consistently, even when EPS performance might have been closer to estimates. Recent news indicates potential challenges, with Q1 2026 adjusted EBITDA reported as weaker-than-expected due to cost pressures and workforce reductions, signaling potential margin resilience issues despite ongoing investments. This news suggests a focus on cost-saving measures and regulatory headwinds. Moving forward, investors will be watching for the effectiveness of these workforce adjustments and any further commentary on cost controls and regulatory pressures in the upcoming quarters.

EPS

EstBeatMiss
$5.38$6.13$6.87$7.61$8.35Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$7.38 - -
Q1'26$7.13$7.15+0.3%
Q4'25$7.53$8.01+6.4%
Q3'25$5.73$6.96+21.6%
Q2'25$6.32$6.84+8.2%
Q1'25$5.75$6.45+12.1%

Revenue

EstBeatMiss
$18.1B$18.6B$19.1B$19.6B$20.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$19.5B - -
Q1'26$19.1B$19.1B+0.2%
Q4'25$19.9B$19.5B-1.8%
Q3'25 - $19.2B -
Q2'25 - $18.6B -
Q1'25 - $18.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

HCA Stock Snapshot

HCA is currently trading at $392.97, giving HCA Healthcare, Inc. a market cap of 87.42B and a P/E ratio of 12.9. Today's range spans $388.01–$394.98, with shares opening at $389.60 and moving down $1.10 (0.3%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 43/100.

Over the past year HCA has traded between $330.00 and $556.52 - the current price is +19.1% off the 52-week low and -29.4% from the high.

HCA Healthcare, Inc. (HCA) is a large-cap in Healthcare with 87.42B in market cap, and the current technical read is bearish. Score: 32/100 (SELL). Sentiment: neutral at 43/100. Price: $392.97 (in the lower half of its 52-week range). The current P/E ratio stands at 12.9. The 52-week range of $330.00–$556.52 provides the structural context, and the current SELL designation suggests that prior support levels are more important to watch than usual.

The current SELL phase for HCA (32/100) at $392.97 (in the lower half of its 52-week range) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 43/100 (neutral) confirms that news flow is not providing a counternarrative. At 87.42B in Healthcare capitalization, HCA has the liquidity for institutional exits to be orderly — but orderly doesn't mean shallow within the $330.00–$556.52 range.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…